Broadfin Capital, LLC historic quarter change: USA Stocks, Reduced
In share positions in stocks (listed in the US), over 13 quarters from 2013-06-30 to 2016-09-30, Broadfin Capital, LLC opened 26 positions, added to 33, reduced 48 and sold out of 30.
- Q3 2016: Stock ANGO; Country of operation United States; Class COM; Shares before 3,607,282.
- Q2 2016: Stock HRTX; Country of operation United States; Class COM; Shares before 1,465,475.
- Q1 2016: Stock HRTX; Country of operation United States; Class COM; Shares before 2,232,001.
- Q1 2016: Stock DVAX; Country of operation United States; Class COM NEW; Shares before 629,710.
Each consecutive pair of Form 13F-HR filings compared (SEC CIK 1511901), 13 quarters: Q3 2016 (2016-06-30 to 2016-09-30, filed 2016-11-14); Q2 2016 (2016-03-31 to 2016-06-30, filed 2016-08-15); Q1 2016 (2015-12-31 to 2016-03-31, filed 2016-05-16); Q4 2015 (2015-09-30 to 2015-12-31, filed 2016-02-16); Q3 2015 (2015-06-30 to 2015-09-30, filed 2015-11-16); Q2 2015 (2015-03-31 to 2015-06-30, filed 2015-08-14); Q1 2015 (2014-12-31 to 2015-03-31, filed 2015-05-15); Q4 2014 (2014-09-30 to 2014-12-31, filed 2015-02-17); Q3 2014 (2014-06-30 to 2014-09-30, filed 2014-11-14); Q2 2014 (2014-03-31 to 2014-06-30, filed 2014-08-14); Q1 2014 (2013-12-31 to 2014-03-31, filed 2014-05-15); Q4 2013 (2013-09-30 to 2013-12-31, filed 2014-02-28); Q3 2013 (2013-06-30 to 2013-09-30, filed 2013-11-14). Rows for the same security, class and put/call are added together. Value change is the filed value at each quarter end, so it includes the price move. Only the filings held here are compared; the firm's 13F-HR filings go back to the quarter ended 2010-12-31.
| Quarter | Stock | Country of operation | Class | Shares before | Shares after | Share change | Value before | Value after | Value change | Filed |
|---|
| Q3 2016 | ANGO
ANGIODYNAMICS INC | United States | COM | 3,607,282 | 2,890,679 | -716,603 | $51,837,000 | $50,703,000 | -$1,134,000 | 2016-11-14 |
|---|
| Q2 2016 | HRTX
HERON THERAPEUTICS INC | United States | COM | 1,465,475 | 1,250,104 | -215,371 | $27,829,000 | $22,564,000 | -$5,265,000 | 2016-08-15 |
|---|
| Q1 2016 | HRTX
HERON THERAPEUTICS INC | United States | COM | 2,232,001 | 1,465,475 | -766,526 | $59,594,000 | $27,829,000 | -$31,765,000 | 2016-05-16 |
|---|
| Q1 2016 | DVAX
DYNAVAX TECHNOLOGIES CORP | United States | COM NEW | 629,710 | 547,810 | -81,900 | $15,214,000 | $10,540,000 | -$4,674,000 | 2016-05-16 |
|---|
| Q1 2016 | ARDX
ARDELYX INC | United States | COM | 349,290 | 216,180 | -133,110 | $6,329,000 | $1,680,000 | -$4,649,000 | 2016-05-16 |
|---|
| Q1 2016 | VCYT
VERACYTE INC | United States | COM | 304,980 | 97,298 | -207,682 | $2,196,000 | $525,000 | -$1,671,000 | 2016-05-16 |
|---|
| Q4 2015 | EBS
EMERGENT BIOSOLUTIONS INC | United States | COM | 1,621,832 | 672,922 | -948,910 | $46,206,000 | $26,924,000 | -$19,282,000 | 2016-02-16 |
|---|
| Q4 2015 | DVAX
DYNAVAX TECHNOLOGIES CORP | United States | COM NEW | 789,710 | 629,710 | -160,000 | $19,379,000 | $15,214,000 | -$4,165,000 | 2016-02-16 |
|---|
| Q4 2015 | ARDX
ARDELYX INC | United States | COM | 549,290 | 349,290 | -200,000 | $9,492,000 | $6,329,000 | -$3,163,000 | 2016-02-16 |
|---|
| Q4 2015 | VCYT
VERACYTE INC | United States | COM | 736,196 | 304,980 | -431,216 | $3,453,000 | $2,196,000 | -$1,257,000 | 2016-02-16 |
|---|
| Q4 2015 | AMPH
AMPHASTAR PHARMACEUTICALS IN | United States | COM | 1,276,979 | 1,026,979 | -250,000 | $14,928,000 | $14,614,000 | -$314,000 | 2016-02-16 |
|---|
| Q3 2015 | HRTX
HERON THERAPEUTICS INC | United States | COM | 2,396,681 | 1,862,001 | -534,680 | $74,681,000 | $45,433,000 | -$29,248,000 | 2015-11-16 |
|---|
| Q3 2015 | EBS
EMERGENT BIOSOLUTIONS INC | United States | COM | 1,760,519 | 1,621,832 | -138,687 | $58,009,000 | $46,206,000 | -$11,803,000 | 2015-11-16 |
|---|
| Q3 2015 | AMPH
AMPHASTAR PHARMACEUTICALS IN | United States | COM | 1,417,956 | 1,276,979 | -140,977 | $24,928,000 | $14,928,000 | -$10,000,000 | 2015-11-16 |
|---|
| Q3 2015 | ATRC
ATRICURE INC | United States | COM | 483,354 | 403,519 | -79,835 | $11,910,000 | $8,841,000 | -$3,069,000 | 2015-11-16 |
|---|
| Q3 2015 | ARAY
ACCURAY INC | United States | COM | 1,000,000 | 750,000 | -250,000 | $6,740,000 | $3,746,000 | -$2,994,000 | 2015-11-16 |
|---|
| Q3 2015 | IRMD
IRADIMED CORP | United States | COM | 355,684 | 230,358 | -125,326 | $8,277,000 | $5,612,000 | -$2,665,000 | 2015-11-16 |
|---|
| Q3 2015 | FATE
FATE THERAPEUTICS INC | United States | COM | 1,300,000 | 1,113,986 | -186,014 | $8,411,000 | $5,938,000 | -$2,473,000 | 2015-11-16 |
|---|
| Q3 2015 | ARDX
ARDELYX INC | United States | COM | 649,290 | 549,290 | -100,000 | $8,877,000 | $9,492,000 | +$615,000 | 2015-11-16 |
|---|
| Q2 2015 | HRTX
HERON THERAPEUTICS INC | United States | COM | 2,808,173 | 2,396,681 | -411,492 | $40,859,000 | $74,681,000 | +$33,822,000 | 2015-08-14 |
|---|
| Q2 2015 | AMPH
AMPHASTAR PHARMACEUTICALS IN | United States | COM | 2,127,854 | 1,417,956 | -709,898 | $31,833,000 | $24,928,000 | -$6,905,000 | 2015-08-14 |
|---|
| Q2 2015 | EBS
EMERGENT BIOSOLUTIONS INC | United States | COM | 1,810,519 | 1,760,519 | -50,000 | $52,071,000 | $58,009,000 | +$5,938,000 | 2015-08-14 |
|---|
| Q2 2015 | IRMD
IRADIMED CORP | United States | COM | 357,364 | 355,684 | -1,680 | $5,443,000 | $8,277,000 | +$2,834,000 | 2015-08-14 |
|---|
| Q2 2015 | ATRC
ATRICURE INC | United States | COM | 533,354 | 483,354 | -50,000 | $10,928,000 | $11,910,000 | +$982,000 | 2015-08-14 |
|---|
| Q1 2015 | ANGO
ANGIODYNAMICS INC | United States | COM | 2,670,703 | 2,398,527 | -272,176 | $50,770,000 | $42,670,000 | -$8,100,000 | 2015-05-15 |
|---|
| Q1 2015 | CNMD
CONMED CORP | United States | COM | 250,000 | 97,657 | -152,343 | $11,240,000 | $4,931,000 | -$6,309,000 | 2015-05-15 |
|---|
| Q1 2015 | ATRC
ATRICURE INC | United States | COM | 825,902 | 533,354 | -292,548 | $16,485,000 | $10,928,000 | -$5,557,000 | 2015-05-15 |
|---|
| Q1 2015 | EBS
EMERGENT BIOSOLUTIONS INC | United States | COM | 2,066,719 | 1,810,519 | -256,200 | $56,277,000 | $52,071,000 | -$4,206,000 | 2015-05-15 |
|---|
| Q1 2015 | IRMD
IRADIMED CORP | United States | COM | 360,884 | 357,364 | -3,520 | $4,655,000 | $5,443,000 | +$788,000 | 2015-05-15 |
|---|
| Q4 2014 | EBS
EMERGENT BIOSOLUTIONS INC | United States | COM | 2,080,519 | 2,066,719 | -13,800 | $44,336,000 | $56,277,000 | +$11,941,000 | 2015-02-17 |
|---|
| Q4 2014 | ANGO
ANGIODYNAMICS INC | United States | COM | 2,975,227 | 2,670,703 | -304,524 | $40,820,000 | $50,770,000 | +$9,950,000 | 2015-02-17 |
|---|
| Q4 2014 | INFIQ
INFINITY PHARMACEUTICALS INC | United States | COM | 854,384 | 450,000 | -404,384 | $11,466,000 | $7,601,000 | -$3,865,000 | 2015-02-17 |
|---|
| Q4 2014 | ATRC
ATRICURE INC | United States | COM | 925,902 | 825,902 | -100,000 | $13,629,000 | $16,485,000 | +$2,856,000 | 2015-02-17 |
|---|
| Q4 2014 | IRMD
IRADIMED CORP | United States | COM | 410,884 | 360,884 | -50,000 | $2,880,000 | $4,655,000 | +$1,775,000 | 2015-02-17 |
|---|
| Q4 2014 | XNCR
XENCOR INC | United States | COM | 753,683 | 520,881 | -232,802 | $7,017,000 | $8,355,000 | +$1,338,000 | 2015-02-17 |
|---|
| Q3 2014 | ATRC
ATRICURE INC | United States | COM | 985,193 | 925,902 | -59,291 | $18,108,000 | $13,629,000 | -$4,479,000 | 2014-11-14 |
|---|
| Q3 2014 | XNCR
XENCOR INC | United States | COM | 774,881 | 753,683 | -21,198 | $9,004,000 | $7,017,000 | -$1,987,000 | 2014-11-14 |
|---|
| Q3 2014 | CPRX
CATALYST PHARM PARTNERS INC | United States | COM | 2,400,000 | 1,400,000 | -1,000,000 | $6,072,000 | $4,648,000 | -$1,424,000 | 2014-11-14 |
|---|
| Q1 2014 | SRPT
SAREPTA THERAPEUTICS INC | United States | COM | 726,655 | 151,655 | -575,000 | $14,801,000 | $3,644,000 | -$11,157,000 | 2014-05-15 |
|---|
| Q1 2014 | XNCR
XENCOR INC | United States | COM | 874,000 | 774,881 | -99,119 | $7,988,000 | $9,089,000 | +$1,101,000 | 2014-05-15 |
|---|
| Q4 2013 | ANGO
ANGIODYNAMICS INC | United States | COM | 2,826,651 | 2,497,049 | -329,602 | $37,312,000 | $42,849,000 | +$5,537,000 | 2014-02-28 |
|---|
| Q4 2013 | EBS
EMERGENT BIOSOLUTIONS INC | United States | COM | 1,074,248 | 1,074,048 | -200 | $20,464,000 | $24,692,000 | +$4,228,000 | 2014-02-28 |
|---|
| Q4 2013 | ATRC
ATRICURE INC | United States | COM | 677,543 | 437,495 | -240,048 | $7,439,000 | $8,172,000 | +$733,000 | 2014-02-28 |
|---|
| Q3 2013 | IART
INTEGRA LIFESCIENCES HLDGS C | United States | COM NEW | 502,914 | 221,391 | -281,523 | $18,422,000 | $8,911,000 | -$9,511,000 | 2013-11-14 |
|---|
| Q3 2013 | ALKS
ALKERMES PLC | | SHS | 600,000 | 450,000 | -150,000 | $17,208,000 | $15,129,000 | -$2,079,000 | 2013-11-14 |
|---|
| Q3 2013 | INSM
INSMED INC | United States | COM PAR $.01 | 291,740 | 165,145 | -126,595 | $3,489,000 | $2,578,000 | -$911,000 | 2013-11-14 |
|---|
| Q3 2013 | MASI
MASIMO CORP | United States | COM | 250,837 | 165,837 | -85,000 | $5,318,000 | $4,418,000 | -$900,000 | 2013-11-14 |
|---|
| Q3 2013 | ATRC
ATRICURE INC | United States | COM | 791,841 | 677,543 | -114,298 | $7,522,000 | $7,439,000 | -$83,000 | 2013-11-14 |
|---|
Similar Firms
| Firm Name | Country | 13F Value | Holdings |
|---|
| Not available yet |